Dafinchi AI

NNOX

Healthcare

Nanox is on track to meet its goal of 100 system installations by the end of 2025, with over 20 systems currently operational and scanning patients.
The company has expanded its pipeline significantly, with a focus on U.S. small- and medium-sized clinics and several European countries including Romania and Greece.
A notable installation is at Keiser University, integrating Nanox.ARC into radiology education, which aims to train future radiologists early in their careers.
Nanox is developing a mobile imaging solution that will bring high-quality diagnostics directly to clinics via a traveling medical imaging vehicle, expanding access and revenue opportunities.

NNOX

Healthcare

AI solutions revenue remained flat at $0.1 million but continued to incur a gross loss of $2.0 million.
Gross loss on a GAAP basis was $3.2 million, slightly higher than $2.9 million in Q2 2024.
Imaging systems and OEM services revenue rose to $221,000 with a gross loss of $1.7 million.
Nanox reported a GAAP net loss of $14.7 million in Q2 2025, compared to $13.6 million in Q2 2024.
Non-GAAP gross loss margin increased to approximately 21% from 9% in the comparable period.
Operating expenses remained relatively stable with R&D at $4.8 million and sales and marketing expenses increasing to $1.2 million.
Revenue for Q2 2025 was $3.0 million, up from $2.7 million in the prior year period.
Teleradiology services revenue increased to $2.7 million with a gross profit margin of 18% on a GAAP basis.

ARCT

Healthcare

1mo

The company is enrolling adult CF patients in a Phase II trial with inhaled ARCT-032, targeting non-responders to CFTR modulators.
Enrollment of the second cohort at 10-milligram dose is expected to complete in early September 2025, with interim data anticipated in September.
The trial focuses on a challenging patient population with severe unmet medical needs, emphasizing safety and lung function improvements.
Regulatory discussions with the FDA are planned for the first half of 2026 to align on pivotal trial design, including adolescent and pediatric enrollment.
The company highlights the potential for inhaled mRNA therapy to be a significant breakthrough for CF non-responders, differentiating from systemic small molecule modulators.
Dosing at 280 mg over 28 days is a novel approach, supported by proprietary delivery technology and drug purification methods.

RDNT

Healthcare

1mo

TechLive, FDA-cleared, enables remote scanning of MRI, CT, PET/CT, and ultrasound procedures, significantly improving operational efficiency.
In a pilot at 64 New York locations, TechLive reduced MRI room closures by 42% in Q2 2025 compared to Q2 2024.
Implementation of TechLive has expanded center operating hours, allowing for more procedures without additional staffing, with a potential capacity increase of up to 40% in busy centers.
The technology has demonstrated the ability to staff exam rooms more effectively, reducing closures and increasing patient throughput, especially in high-demand markets.
RadNet aims to connect over 300 systems with TechLive by early 2026, which could substantially increase advanced imaging capacity and revenue.

RDNT

Healthcare

1mo

Adjusted EBITDA reached a quarterly record of $81.2 million, up 12.3% from the prior year, with margin expansion to 16.3% from 15.7%.
Advanced imaging procedures increased to 27.5% of total procedures, with MRI up 6.6%, CT up 5.9%, and PET/CT up 16.2% on a same-center basis.
Cash balance was strong at $833 million with net debt to adjusted EBITDA ratio below 1x, reflecting solid liquidity and leverage management.
Digital Health segment revenue grew 30.9% to $20.7 million, driven by AI-powered breast cancer screening and expanded licensing.
RadNet reported record quarterly revenue of $498.2 million in Q2 2025, an 8.4% increase year-over-year.

Earnings Feed